PharmacoEconomics

, Volume 11, Issue 5, pp 408–418 | Cite as

Cost Considerations in the Pharmacological Prevention and Treatment of Stroke

  • Andrei V. Alexandrov
  • Liliana T. Smurawska
  • William Bartle
  • Paul Oh
Review Article

Summary

Stroke remains the leading cause of neurological disability and the third leading cause of death worldwide, consuming a large share of total healthcare expenditures.

In this review, we discuss the cost effectiveness of stroke prevention for various risk factor—modification programmes and pharmacological interventions with aspirin (acetylsalicylic acid), ticlopidine and warfarin. Cost considerations and potential cost savings resulting from acute treatment are discussed for parenterally administered anticoagulants, such as heparin and nadroparin, and for intravenous thrombolysis with alteplase (recombinant tissue plasminogen activator; r-tPA). Patients with multiple risk factors for stroke require more aggressive prevention strategies which are associated with a greater risk of complications. The rates of complications, particularly intracerebral haemorrhage, should be kept low to achieve cost benefits for warfarin and alteplase. Reduced hospital length of stay is the key factor in the implementation of cost-effective stroke therapies.

The analysis of future clinical trials of new stroke therapies should also include economic parameters, such as length of hospital stay and intensity of resource usage, to help guide formulary and therapeutic decisions.

Keywords

Aspirin Atrial Fibrillation Warfarin Acute Stroke Acute Ischemic Stroke 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    American Heart Association. 1992 Heart and stroke facts. Dallas: American Heart Association, 1992Google Scholar
  2. 2.
    Lanska DJ, Kryscio R. Geographic distribution of hospitalization rates, case fatality, and mortality from stroke in the United States. Neurology 1995; 45: 634–40CrossRefGoogle Scholar
  3. 3.
    Emanuel EJ, Emanuel LL. The economics of dying — the illusion of cost savings at the end of life. N Engl J Med 1994; 330: 540–4PubMedCrossRefGoogle Scholar
  4. 4.
    Kawachi I, Malcolm LA. The cost-effectiveness of treating mild-to-moderate hypertension: a reappraisal. J Hypertension 1991; 9: 199–208CrossRefGoogle Scholar
  5. 5.
    Rocella EJ, Lenfant C. Considerations regarding the cost and effectiveness of public and patient education programmes. J Hum Hypertens 1992; 6: 463–7Google Scholar
  6. 6.
    Gorelick PB. Stroke prevention: an opportunity for efficient utilization of health care resources during the coming decade. Stroke 1994; 25: 220–4PubMedCrossRefGoogle Scholar
  7. 7.
    Broderick JP, Phillips SJ, Whisnant JP, et al. Incidence rates of stroke in the eighties: the end of the decline in stroke? Stroke 1989; 20: 577–82PubMedCrossRefGoogle Scholar
  8. 8.
    Wolf PA, D’Agostino RB, O’Neal A, et al. Secular trends in stroke incidence and mortality: the Framingham study. Stroke 1992; 23: 1551–5PubMedCrossRefGoogle Scholar
  9. 9.
    North American Symptomatic Carotid Endaretectomy Trial Collaborators. Beneficial effect of carotid endarterectomy in symptomatic patients with high grade carotid stenosis. N Engl J Med 1991; 325: 445–53CrossRefGoogle Scholar
  10. 10.
    Executive Committee for the Asymptomatic Carotid Atherosclerosis Study. Endarterectomy for asymptomatic carotid artery stenosis. JAMA 1995; 273: 1421–8CrossRefGoogle Scholar
  11. 11.
    Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease. Part 2. Short-term reductions in blood pressure: overview of randomized drug trials in their epidemiological context. Lancet 1990; 335: 827–38PubMedCrossRefGoogle Scholar
  12. 12.
    Weinstein MC, Stason WB. Allocation of resources to manage hypertension. N Engl J Med 1977; 296: 732–7PubMedCrossRefGoogle Scholar
  13. 13.
    Edelson JT, Weinstein MC, Tosteson ANA, et al. Long-term cost-effectiveness of various initial monotherapies for mild to moderate hypertension. JAMA 1990; 263: 408–13CrossRefGoogle Scholar
  14. 14.
    Gafni A. On the costs of treating mild hypertension. J Gen Intern Med 1987; 2: 441–3PubMedCrossRefGoogle Scholar
  15. 15.
    Millikan C, Futrell N. The strange story of aspirin and the prevention of stroke. J Stroke Cerebrovasc Dis 1995; 5: 248–54CrossRefGoogle Scholar
  16. 16.
    Barnett HJM, Eliasziw M, Meldrum HE. Drugs and surgery in the prevention of ischemic stroke. N Engl J Med 1995; 332: 238–48PubMedCrossRefGoogle Scholar
  17. 17.
    Solomon DH, Hart RG. Antithrombotic therapies for stroke prevention. Curr Opin Neurol 1994; 7: 48–53PubMedCrossRefGoogle Scholar
  18. 18.
    Antiplatelet Trialists Collaboration. Collaborative overview of randomised trials of antiplatelet therapy — I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81–106CrossRefGoogle Scholar
  19. 19.
    Hass WK, Easton JD, Adams Jr HP, et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. N Engl J Med 1989; 321: 501–7PubMedCrossRefGoogle Scholar
  20. 20.
    Oster G, Huse DM, Lacey MJ, et al. Cost-effectiveness of ticlopidine in preventing stroke in high-risk patients. Stroke 1994; 25: 1149–56PubMedCrossRefGoogle Scholar
  21. 21.
    Van Gijn J, Algra A. Ticlopidine, trials, and torture. Stroke 1994; 25: 1097–8PubMedCrossRefGoogle Scholar
  22. 22.
    Warlow CP. Ticlopidine, a new antithrombotic drug: but is it better than aspirin for long-term use? J Neurol Neurosurg Psychiatry 1990; 53: 185–7PubMedCrossRefGoogle Scholar
  23. 23.
    Bladin CF, Norris JW. Relative benefits of ticlopidine and aspirin [letter]. Stroke 1994; 25: 2290PubMedCrossRefGoogle Scholar
  24. 24.
    Roderick J, Wilkes HC, Meade TW. The gastrointestinal toxicity of aspirin: an overview of randomized controlled trials. Br J Clin Pharmacol 1993; 35: 219–26PubMedCrossRefGoogle Scholar
  25. 25.
    Smurawska LT, Alexandrov AV, Bladin CF, et al. Cost of acute stroke care in Toronto, Canada. Stroke 1994; 25: 1628–31PubMedCrossRefGoogle Scholar
  26. 26.
    Feinberg WM, Blackshear JL, Laupacis A, et al. Prevalence, age distribution, and gender of patients with atrial fibrillation. Arch Intern Med 1995; 155: 469–73PubMedCrossRefGoogle Scholar
  27. 27.
    Boston Area Anticoagulation Trial for Atrial Fibrillation investigators. The effect of low-dose warfarin on the risk of stroke in patients with non-rheumatic atrial fibrillation. N Engl J Med 1990; 323: 1505–11CrossRefGoogle Scholar
  28. 28.
    Stroke Prevention in Atrial Fibrillation investigators. Stroke prevention in atrial fibrillation study: final results. Circulation 1991; 84: 527–39CrossRefGoogle Scholar
  29. 29.
    Gage BF, Cardinalli AB, Albers GW, et al. Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation. JAMA 1995; 274: 1839–45PubMedCrossRefGoogle Scholar
  30. 30.
    European Atrial Fibrillation Trial Study group. Secondary stroke prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993; 342: 1255–62Google Scholar
  31. 31.
    Petersen P, Boysen G, Godtfredsen J, et al. Placebo-controlled, randomized trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: the Copenhagen AFASAK Study. Lancet 1989; II: 175–9CrossRefGoogle Scholar
  32. 32.
    Laupacis A, Boysen G, Connolly S, et al. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Arch Intern Med 1994; 154: 1449–57CrossRefGoogle Scholar
  33. 33.
    Gustafsson C, Asplund K, Britton M, et al. Cost effectiveness of primary stroke prevention in atrial fibrillation: Swedish national perspective. BMJ 1992; 305: 1457–60PubMedCrossRefGoogle Scholar
  34. 34.
    Camarata PJ, Heros RC, Latchaw RE. Brain attack: the rationale for treating stroke as a medical emergency. Neurosurgery 1994; 34: 144–58PubMedCrossRefGoogle Scholar
  35. 35.
    Rothrock JF, Hart RG. Antithrombotic therapy in cerebrovascular disease. Arch Intern Med 1991; 115: 885–95Google Scholar
  36. 36.
    Biller J, Love BB, Gordon DE. Antithrombotic therapy for ischemic cerebrovascular disease. Semin Neurol 1991; 11: 353–67PubMedCrossRefGoogle Scholar
  37. 37.
    The International Stroke Trial Collaborative Group. The international stroke trial. Preliminary results part II: effects of heparin [abstract]. Stroke 1997; 28: 231Google Scholar
  38. 38.
    Cerebral Embolism Study Group. Immediate anticoagulation of embolic stroke: a randomized trial. Stroke 1983; 14: 668–76CrossRefGoogle Scholar
  39. 39.
    Duke RJ, Bloch RF, Turpie AG, et al. Intravenous heparin for prevention of stroke progression in acute partial stable stroke. Ann Intern Med 1986; 105: 825–8PubMedGoogle Scholar
  40. 40.
    Kay R, Wong KS, Yu YL, et al. Low-molecular-weight heparin for the treatment of acute ischemic stroke. N Engl J Med 1995; 333: 1588–93PubMedCrossRefGoogle Scholar
  41. 41.
    Kay R, Woo J, Kreel L, et al. Stroke subtypes among Chinese living in Hong Kong: the Shatei stroke registry. Neurology 1992; 42: 985–7PubMedCrossRefGoogle Scholar
  42. 42.
    Multicenter Acute Stroke Trial — Europe Study Group. Thrombolytic therapy with streptokinase in acute ischemic stroke. N Engl J Med 1996; 335: 145–50CrossRefGoogle Scholar
  43. 43.
    Donnan G, Davis SM, Chambers BR, et al. Trials of streptokinase in severe acute ischaemic stroke [letter]. Lancet 1995; 345: 578–9PubMedCrossRefGoogle Scholar
  44. 44.
    Multicentre Acute Stroke Trial — Italy (MAST-I) Group. Randomized controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Lancet 1995; 346: 1509–14Google Scholar
  45. 45.
    Hacke W, Kaste M, Fieschi C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke: the European Cooperative Acute Stroke Study (ECASS). JAMA 1995; 274: 1017–25PubMedCrossRefGoogle Scholar
  46. 46.
    National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995; 333: 1581–7CrossRefGoogle Scholar
  47. 47.
    Levy DE, Brott TG, Haley Jr EC, et al. Factors related to hematoma formation in patients receiving tissue-type plasminogen activator for acute ischemic stroke. Stroke 1994; 25: 291–7PubMedCrossRefGoogle Scholar
  48. 48.
    Fagan S, Morgenstern LB, Petitta A, et al. rt-PA Reduces length of stay and improves disposition following stroke [abstract]. Stroke 1997; 28: 272Google Scholar
  49. 49.
    Stegmayr B, Asplund K. Diabetes as a risk factor for stroke: a population perspective. Diabetologia 1995; 38: 1061–8PubMedCrossRefGoogle Scholar
  50. 51.
    Working Group on Emergency Brain Resuscitation. Emergency Brain Resuscitation. Ann Intern Med 1995; 122: 622–7Google Scholar
  51. 52.
    Langehorn P, Williams BO, Gilchrist W, et al. Do stroke units save lives? Lancet 1993; 342: 395–8CrossRefGoogle Scholar
  52. 53.
    Jorgensen HS, Nakayama H, Raaschou HO, et al. The effect of a stroke unit: reductions in mortality, discharge rate to nursing home, length of stay, and cost. A community-based study. Stroke 1995; 26: 1178–82PubMedCrossRefGoogle Scholar
  53. 54.
    Baron JC, von Kummer R, del Zoppo GL. Treatment of acute ischemic stroke: challenging the concept of a rigid and universal time window. Stroke 1995; 26: 2219–21PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1997

Authors and Affiliations

  • Andrei V. Alexandrov
    • 1
  • Liliana T. Smurawska
    • 1
  • William Bartle
    • 1
  • Paul Oh
    • 1
  1. 1.Stroke Research Unit and the Division of Clinical Pharmacology, Sunnybrook Health Science CentreTorontoCanada

Personalised recommendations